Revenue ($USD) : $1,309,055,000
R&D spend : $54,435,000
Employees : 3,657
Fiscal year end : 3/30/2024
CEO : Christopher Simon

www.haemonetics.com

Haemonetics technologies serve medical markets including blood and plasma component collection, the surgical suite and hospital transfusion. The company has been active in M&A, acquiring cardiology-focused medical device company OpSens for $255 million in 2023 and esophagus-protecting devicemaker Attune Medical for $160 million in 2024. –CN and SW